Article in Medical Life Sciences News: Uniqsis FlowSyn continuous flow reactor helps simplify scale-up of API batch processes
Arcinova, a Quotient Sciences business, puchased a Uniqsis FlowSyn Continuous Flow Reator to support our drug substance capabilities.
Quotient Clinical announces second US acquisition: QS Pharma
Quotient Sciences, the early phase drug development services provider, today announces that it has acquired QS Pharma, the contract development and manufacturing organisation (CDMO), based near Philadelphia, US, from Charles River Laboratories International, Inc.
Quotient Clinical expands into USA through acquisition of SeaView Research, the specialist clinical pharmacology business
Quotient Sciences, the early phase drug development services provider, today announces that it has acquired SeaView Research.
Quotient’s Simon Lee elected as Secretary of EUCROF
Quotient Sciences, the innovative provider of early phase drug development services, is pleased to announce that Chief Compliance Officer, Simon Lee, has been elected as Secretary of the European CRO Federation (“EUCROF”).
Quotient Clinical wins a BVCA Management Team of the Year Award
Quotient Sciences, the unique and innovative provider of drug development services, today announced it has received a British Private Equity & Venture Capital Association (BVCA) Management Team Award.
Quotient Clinical Expands Data Sciences Capability
Quotient Sciences, the Translational Pharmaceutics® company, a leading provider of early stage and specialist drug development services, today announced the expansion of its Data Sciences function with relocation to a larger office, staying in Edinburgh.